Major Program
NCI Community Oncology Research Program
Research Group
Community Oncology and Prevention Trials
Sponsor
SWOG Cancer Research Network
Status
Active, not recruiting
ClinicalTrials.gov ID
For more information, see ClinicalTrials.gov NCT01349881
The investigators hypothesize that the combination of eflornithine and sulindac will be effective in reducing a three-year event rate of adenomas and second primary colorectal cancers in patients previously treated for Stages 0 through III colon or rectal cancer.
Intervention
Eflornithine placebo & sulindac, Eflornithine placebo & sulindac placebo, Eflornithine plus sulindac, eflornithine & sulindac placebo
Condition
Colorectal Neoplasms
Investigators
Jason A. Zell, D.O., MPH